- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs | ||
| Mi | Insmed wins FDA approval for future blockbuster Brinsupri | ||
| Mi | PureTech forms respiratory spin-off Celea to advance deuterated pirfenidone | ||
| Mi | Amphastar and Anji make licence agreement for three new peptides | ||
| Mi | How to solve the big challenges of cell and gene therapy manufacturing | ||
| Mi | A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm | ||
| Mi | AbbVie expands North Chicago API production with $195m investment | ||
| Di | Podcast: US tariff news and Q2 earnings influence pharma trends | ||
| Di | Eli Lilly and GSK drive South Korea's drug licensing activity | ||
| Di | Third time lucky as PharmaTher gets FDA approval for ketamine | ||
| Di | Prasad's shock FDA return reignites regulatory uncertainty | ||
| Di | Sartorius to invest $3m for minority share in biotech start-up Nanotein | ||
| Di | Fosun and Expedition make $645m licensing deal for respiratory drug | ||
| Mo | Lilly first to opt for confidential reimbursement price in Germany | ||
| Mo | Uncertainty around tariffs is a disincentive for pharma onshoring in the US | ||
| Mo | GSK's oral antibiotic for gonorrhoea set for FDA review | ||
| Mo | Japan MHLW approves Biostar's angel stem cell therapy for autism | ||
| Mo | Boehringer's Hernexeos receives fast-tracked FDA approval | ||
| Mo | FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer | ||
| Fr | Podcast: ePRO explained | ||
| Fr | EpiPen patent expiry opens new era for innovation | ||
| Fr | Gilead's Yeztugo sales "ahead of expectations" following launch | ||
| Fr | Uncertainty looms over FDA scheme to boost US manufacturing | ||
| Fr | Epkinly breaks ground in Phase III FL trial | ||
| Fr | FDA removes Ixchiq partial pause but tightens vaccine's use |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .